Here is the problem
NICE guidance recommends GLP-1 receptor agonists for type 2 diabetes when triple therapy is insufficient and specific BMI criteria are met, or for weight management in adults with BMI 30 kg/m (or 27 kg/m with comorbidities) through specialist services
Route of administration and lifestyle fit For patients, the biggest differences lie in how these medications fit into their current lifestyle and life stage: Oral GLP1s require daily dosing Injectables are once weekly but require needles Roughly one in four adults has needle aversion, and oral options may open the door for patients previously unwilling or unable to use injectables
[79] observed some improvement with sitagliptin [79]
402, Issue 10401, Aug 12, 2023, pp
However, knockdown or deletion of TET2 shifts the gene expression profiles of these myeloid cells toward a pro-inflammatory phenotype, impairing their suppressive capabilities and promoting anti-tumor immune responses [100]